Company performance
Add to research
Current Price
as of Feb 11, 2025$55.13
P/E Ratio
N/A
Market Cap
$4.1B
Description
Add to research
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
Metrics
Add to research
Overview
- HQStamford, CT
- SectorHealth Technology
- IndustryBiotechnology
- TickerSWTX
- Price$55.13+2.09%
Trading Information
- Market cap$4.10B
- Float88.02%
- Average Daily Volume (1m)2,656,503
- Average Daily Volume (3m)1,782,985
- EPS-$3.73
Company
- Revenue$135.49M
- Rev growth (1yr)N/A
- Net income-$53.53M
- Gross margin91.44%
- EBITDA margin-115.74%
- EBITDA-$57.06M
- EV$2.01B
- EV/Revenue14.83
- P/EN/A
- P/S30.22
- P/B7.69
- Debt/Equity1.30
Documents
Add to research
SEC Filings
Factset Street Account